Guidelines for Sclerotherapy of Varicose Veins (ICD 10: I83.0, I83.1, I83.2, and I83.9)

Rabe, Eberhard; Pannier-Fischer, F.; Gerlach, H.; Breu, Franz Xaver; Guggenbichler, S.; Zabel, M

doi:10.1097/00042728-200405000-00001

Cited by 7 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polidocanol was originally developed as a detergent. It is an anionic surfactant that is cytotoxic for endothelial cells and can lyse erythrocytes, leukocytes, and platelets . It can activate intracellular signaling pathways that regulate intracellular calcium release and nitric oxide production, further inducing cellular injury or death.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of polidocanol sclerotherapy in mucocele of the minor salivary gland

Liu

Zhang

Jiang

et al. 2018

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy of polidocanol sclerotherapy in mucocele of the minor salivary gland

Liu

Zhang

Jiang

et al. 2018

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…The presence of alcohol may put patients taking disulfiram at risk, although no complications involving this agent and disulfiram have been reported. Consensus guidelines 32 do not cite disulfiram use as a contraindication to the use of this agent.…”

Section: Potential Drug Interactionsmentioning

confidence: 99%

Sclerosants

Duffy

2010

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…There are both absolute and relative contraindications for its use [43] in any form. The absolute contraindications include known allergy, presence of acute superficial or deep vein thrombosis, advanced peripheral arterial occlusive disease, first trimester and late (post 36 weeks) pregnancy, and immobility.…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Polidocanol for endovenous microfoam sclerosant therapy

Eckmann¹

2009

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Background-Polidocanol is a liquid surfactant having endothelial cell lytic properties. In the form of a controlled, dispensed microfoam it is administered endovenously as a sclerosing agent in the treatment of varicose veins.Objective-This review summarizes efficacy of polidocanol endovenous microfoam sclerotherapy using a proprietary dispensing system to control foam characteristics and gas content for treating varicose veins. Methods-We reviewed in-vitro, Phase I, Phase II and limited Phase III data for polidocanol microfoam with a focus on controlled foam formulation in therapyResults/conclusions-Clinical trials of controlled dispensing of polidocanol microfoam provide evidence of effective treatment of chronic venous insufficiency with low toxicity, minimal risk and few complications.

show abstract

Guidelines for Sclerotherapy of Varicose Veins (ICD 10: I83.0, I83.1, I83.2, and I83.9)

Cited by 7 publications

References 20 publications

The efficacy of polidocanol sclerotherapy in mucocele of the minor salivary gland

The efficacy of polidocanol sclerotherapy in mucocele of the minor salivary gland

Sclerosants

Polidocanol for endovenous microfoam sclerosant therapy

Contact Info

Product

Resources

About